Cefditoren


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Community-acquired pneumonia 400 mg bid for 14 days. Acute bacterial exacerbation of chronic bronchitis 400 mg bid for 10 days. Pharyngitis; Tonsilitis; Uncomplicated skin and skin structure infections 200 mg bid for 10 days.
Dosage Details
Oral
Pharyngitis, Tonsillitis, Uncomplicated skin and skin structure infections
Adult: 200 mg bid for 10 days.

Oral
Community-acquired pneumonia
Adult: 400 mg bid for 14 days.

Oral
Acute bacterial exacerbation of chronic bronchitis
Adult: 400 mg bid for 10 days.
Renal Impairment
CrCl (mL/min)
Dosage
<30 Max: 200 mg once daily.
30-49 Max: 200 mg bid.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to cefditoren, other cephalosporins, or milk proteins. Carnitine deficiency or an inborn error of metabolism.
Special Precautions
Patient w/ history of penicillin allergy and seizure disorder; poor nutritional status. Hepatic or renal impairment. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, nausea, headache, abdominal pain, vag moniliasis, dyspepsia, vomiting, haematuria, increased urine WBC, glucose or INR, decreased haematocrit.
Potentially Fatal: Hypersensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, Clostridium difficile-associated diarrhoea and colitis.
MonitoringParameters
Monitor renal function. Observe for signs and symptoms of anaphylaxis during 1st dose.
Overdosage
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea, convulsions. Management: Symptomatic and supportive treatment. Haemodialysis may be useful in the removal from the body.
Drug Interactions
Decreased absorption w/ antacids or H2-receptor antagonists. Increased plasma concentrations w/ probenecid.
Food Interaction
Increased bioavailability when given w/ a high-fat meal.
Lab Interference
May induce positive direct Comb's test. False-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln. False negative result may occur in ferricyanide test.
Action
Description: Cefditoren binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Increased bioavailability when given w/ a high-fat meal. Bioavailability: Approx 14% (fasting state). Time to peak plasma concentration: 1.5-3 hr.
Distribution: Volume of distribution: 9.3±1.6 L. Plasma protein binding: 88% (primarily to albumin).
Metabolism: Not appreciably metabolised. Hydrolysed by esterases to cefditoren (active component) and pivalate.
Excretion: Mainly via urine by glomerular filtration and tubular secretion. Plasma half-life: Approx 1.6 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store at 25°C. Protect from light and moisture.
MIMS Class
ATC Classification
J01DD16 - cefditoren ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by MIMS based on Cefditoren from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in